AnteoTech (ASX:ADO) Maps FY2027 Priorities After AUD 1.9 Million R&D Incentive

Aditi Sarkar

30 September 2026 03:02 PM AEST

AnteoTech (ASX:ADO) Maps FY2027 Priorities After AUD 1.9 Million R&D Incentive

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

AnteoTech received AUD 1.91 million under Australia’s Research and Development Tax Incentive.
The company reported AUD 467,589 in FY2026 sales Revenue and AUD 4.35 million in total revenue.
Operating expenses excluding non-cash items fell to AUD 6.86 million during FY2026.
Management targets customer conversions across Life Sciences and Advanced Battery Technologies in FY2027.

AnteoTech Limited (ASX:ADO) enters FY2027 with fresh cash from its research programme and a sharper focus on converting technology development into commercial activity. The company received AUD 1,905,639 under the Research and Development Tax Incentive, following FY2026 results that showed lower sales revenue alongside reduced operating expenditure.

R&D Incentive Adds to the Funding Position

The cash payment relates to eligible Australian research and development activities across AnteoTech’s Advanced Battery Technologies and Life Science Business units during FY2026. The payment was received after the balance date and is therefore separate from the AUD 11.2 million held in the bank at 30 June 2026. AnteoTech said the incentive supports its ability to fund commercialisation across both business units.

FY2026 Numbers Set the Starting Point

Sales revenue came in at AUD 467,589 for FY2026, compared with AUD 968,878 in FY2025 and AUD 460,397 in FY2024. The FY2025 figure included an additional AUD 276,863 payment from the Serum Institute of India. A further AUD 134,138 sale completed on 7 July 2026 is expected to be recognised in FY2027. Total revenue increased to AUD 4.35 million from AUD 3.46 million in FY2025. Operating expenses excluding non-cash items declined to AUD 6.86 million, extending the reduction from AUD 8.45 million in FY2025 and AUD 10.89 million in FY2024.

Two Platforms Drive the FY2027 Agenda

AnteoTech’s Advanced Battery Technologies portfolio includes Anteo X, Anteo S, Anteo C and the Ultranode series, while its Life Sciences business sells AnteoBind products used in vaccines and diagnostics. For FY2027, the Life Sciences priority is converting customer evaluations into sales across India, the United States, Europe, Japan and South Korea. In batteries, the company plans to focus on sales conversion for Anteo S, Anteo C and Anteo X while progressing joint development agreements for Ultranode 95 aimed at military drones.

What Comes Next

FY2027 execution will centre on converting evaluations and development work into sales, progressing battery collaborations and maintaining financial discipline while supporting the commercial pipeline.

FAQs

Q: How much did AnteoTech receive through the R&D tax incentive?

A: AnteoTech received AUD 1,905,639 in cash under the Research and Development Tax Incentive.

Q: What was AnteoTech’s FY2026 sales revenue?

A: FY2026 sales revenue was AUD 467,589, while total revenue was AUD 4.35 million.

Q: How much cash did AnteoTech hold at 30 June 2026?

A: The company reported AUD 11.2 million in the bank at 30 June 2026.

Q: What are AnteoTech’s FY2027 priorities?

A: Priorities include converting Life Sciences evaluations and battery product opportunities into sales, progressing Ultranode 95 agreements and maintaining financial discipline.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.